Weighing three outpatient treatments for COVID-19, the drug cost watchdog Institute for Clinical and Economic Review (ICER) has determined that Pfizer’s Paxlovid, Merck and Ridgeback Biotherapeutics’ ...

In the search for effective COVID-19 treatments, many drugs failed to live up to their early promise. The antiviral molnupiravir performed well in trials, reducing hospitalizations and deaths among ...

An image showing mutations caused by NHC, the active component of molnupiravir to all genes and proteins of another pathogenic coronavirus, MHV. As much as people are justifiably excited about the ...

SHANGHAI, April 4 (Reuters) - Pfizer (PFE.N), opens new tab and Merck (MRK.N), opens new tab have slightly lowered the prices of their respective Paxlovid and molnupiravir COVID-19 treatments in China ...

A new study suggests that the antiviral Molnupiravir may “paradoxically” be driving COVID-19 mutations, creating variants of concern. What is going on? It is all about molnupiravir’s mode of action ...

As coronavirus cases rage in India, Merck announced that it has entered into non-exclusive voluntary licensing agreements with five manufacturers of generic drugs in that country to speed and expand ...

The company announced a licensing deal that will allow the drug, molnupiravir, to be made and sold cheaply in 105 developing nations. By Stephanie Nolen Merck has granted a royalty-free license for ...